Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell linesLi Wang, Jinhai Tang|Molecular Medicine Reports|2014Cited by 59
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.Zefei Jiang, Hua Yang, Xiaojia Wang et al.|Journal of Clinical Oncology|2022Cited by 36
Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancerYing Zhu, Jinhai Tang|Oncology Letters|2014Cited by 19